Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
about
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsAllotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationA prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignanciesA phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Management of Patients with MYC-Altered Lymphomas.Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantationDonor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?Accelerated therapeutic progress in diffuse large B cell lymphoma.Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation.Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
P2860
Q28066710-07E21636-A393-4571-A6E1-254F5B82A997Q33756719-07000A6E-76F8-4194-862E-CF74D95D5927Q34325329-F82F8E2E-6A74-4B11-A576-F4ACC2C5FEB4Q35213027-7D12C460-5B4C-4D29-8BB4-B549172647D1Q35218515-D1475AB0-2E7E-473D-B4C6-7B8E2BEBC736Q35960027-49298A9D-A10B-4810-AEE1-B6F6436B485DQ36426327-A80FCE13-3167-461B-A385-7F670DA72D8CQ36834194-C9EE7E48-C3C0-4795-B32A-9392926D073BQ36928725-A11D373B-D403-404F-8E34-C590D2DF0385Q37083601-FB665B88-6213-4035-8FA8-E457D92C6EACQ37168346-CE5BB6FF-C5DB-49B0-8308-74A9CF19DABBQ37212916-66387BAE-387C-4746-B97D-0AEE3A1E72E6Q37390239-9EC47C54-EE97-4CC1-93B1-8C47CCF6B763Q37434670-41E07015-4754-4810-87EC-33BE515DDF0DQ38109511-0607A131-FE75-45C7-84D2-508E90D69677Q38174498-291F6AAA-5659-41BC-B001-CAF23A9453D3Q38260183-A8C970B3-3918-4B08-8FA6-BAD86E775F14Q38488058-AF8C4BD1-A07B-4E4D-813F-C7B43A71A50FQ38777460-D852BC1C-45AA-48B2-9B9E-462D7988DCD4Q38860997-17FB45D9-CBC3-4DA1-8462-2D4270DD481EQ40855399-9F022682-C337-4A35-BC3E-B758BE1618AAQ41519709-51096373-7298-4F56-955E-78B589ACBEEBQ42533033-C0F44EE9-138B-4D18-990D-9937BE98745AQ47563827-1E37C98F-239F-4641-942C-3B7FDFD1E4EFQ47603352-E68ADB02-C31B-4E9F-883D-222C8561241BQ48792987-16038CF1-542A-44E5-A428-F2918D888FD2Q52881184-920A6EA4-D07A-4D0A-8B4D-414AC6367FB8Q52970765-784FB754-E772-4D77-8086-C5A80C0A138E
P2860
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Conditioning regimens for allo ...... ablative or reduced intensity?
@ast
Conditioning regimens for allo ...... ablative or reduced intensity?
@en
type
label
Conditioning regimens for allo ...... ablative or reduced intensity?
@ast
Conditioning regimens for allo ...... ablative or reduced intensity?
@en
prefLabel
Conditioning regimens for allo ...... ablative or reduced intensity?
@ast
Conditioning regimens for allo ...... ablative or reduced intensity?
@en
P2093
P2860
P50
P1433
P1476
Conditioning regimens for allo ...... ablative or reduced intensity?
@en
P2093
Cesar O Freytes
Christopher N Bredeson
David J Inwards
Edmund K Waller
Evgeny Klyuchnikov
Ginna G Laport
Harry C Schouten
Jeanette Carreras
John Gibson
Luis M Isola
P2860
P304
P356
10.1182/BLOOD-2012-06-436725
P407
P577
2012-09-24T00:00:00Z